Literature DB >> 18985626

Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy in the rat.

Shane A Perrine1, Mark S Michaels, Farhad Ghoddoussi, Elisabeth M Hyde, Manuel E Tancer, Matthew P Galloway.   

Abstract

Despite the potential for deleterious (even fatal) effects on cardiac physiology, 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) abuse abounds driven mainly by its euphoric effects. Acute exposure to MDMA has profound cardiovascular effects on blood pressure and heart rate in humans and animals. To determine the effects of MDMA on cardiac metabolites in rats, MDMA (0, 5, or 10 mg/kg) was injected every 2 h for a total of four injections; animals were sacrificed 2 h after the last injection (8 h drug exposure), and their hearts removed and tissue samples from left ventricular wall dissected. High resolution magic angle spinning proton magnetic resonance spectroscopy ((1)H-MRS) at 11.7 T, a specialized version of MRS aptly suited for analysis of semi-solid materials such as intact tissue samples, was used to measure the cardiac metabolomic profile, including alanine, lactate, succinate, creatine, and carnitine, in heart tissue from rats treated with MDMA. MDMA effects on MR-visible choline, glutamate, glutamine, and taurine were also determined. Body temperature was measured following each MDMA administration and serotonin and norepinephrine (NE) levels were measured by high pressure liquid chromatography (HPLC) in heart tissue from treated animals. MDMA significantly and dose-dependently increased body temperature, a hallmark of amphetamines. Serotonin, but not NE, levels were significantly and dose-dependently decreased by MDMA in the heart wall. MDMA significantly altered the MR-visible profile with an increase in carnitine and no change in other key compounds involved in cardiomyocyte energy metabolomics. Finally, choline levels were significantly decreased by MDMA in heart. The results are consistent with the notion that MDMA has significant effects on cardiovascular serotonergic tone and disrupts the metabolic homeostasis of energy regulation in cardiac tissue, potentially increasing utilization of fatty acid metabolism. The contributions of serotonergic signaling on MDMA-induced changes in cardiac metabolism remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18985626      PMCID: PMC2882794          DOI: 10.1002/nbm.1352

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  45 in total

Review 1.  The management of conditioned nutritional requirements in heart failure.

Authors:  Marc L Allard; Khursheed N Jeejeebhoy; Michael J Sole
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

2.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

3.  Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial.

Authors:  S J Lester; M Baggott; S Welm; N B Schiller; R T Jones; E Foster; J Mendelson
Journal:  Ann Intern Med       Date:  2000-12-19       Impact factor: 25.391

Review 4.  Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management.

Authors:  A P Hall; J A Henry
Journal:  Br J Anaesth       Date:  2006-04-04       Impact factor: 9.166

Review 5.  Disorders of carnitine transport and the carnitine cycle.

Authors:  Nicola Longo; Cristina Amat di San Filippo; Marzia Pasquali
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-05-15       Impact factor: 3.908

Review 6.  (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.

Authors:  U D McCann; V Eligulashvili; G A Ricaurte
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

7.  Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2.

Authors:  I Tamai; R Ohashi; J Nezu; H Yabuuchi; A Oku; M Shimane; Y Sai; A Tsuji
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

8.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.

Authors:  Vincent Setola; Sandra J Hufeisen; K Jane Grande-Allen; Ivan Vesely; Richard A Glennon; Bruce Blough; Richard B Rothman; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

9.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.

Authors:  D M Stone; D C Stahl; G R Hanson; J W Gibb
Journal:  Eur J Pharmacol       Date:  1986-08-22       Impact factor: 4.432

10.  Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters.

Authors:  S Schuldiner; S Steiner-Mordoch; R Yelin; S C Wall; G Rudnick
Journal:  Mol Pharmacol       Date:  1993-12       Impact factor: 4.436

View more
  13 in total

1.  Metabolic signatures imaged in cancer-induced cachexia.

Authors:  Marie-France Penet; Mayur M Gadiya; Balaji Krishnamachary; Sridhar Nimmagadda; Martin G Pomper; Dmitri Artemov; Zaver M Bhujwalla
Journal:  Cancer Res       Date:  2011-09-26       Impact factor: 12.701

Review 2.  Metabolomics as a tool for cardiac research.

Authors:  Julian L Griffin; Helen Atherton; John Shockcor; Luigi Atzori
Journal:  Nat Rev Cardiol       Date:  2011-09-20       Impact factor: 32.419

3.  'Ecstasy' enhances noise-induced hearing loss.

Authors:  Michael W Church; Jinsheng S Zhang; Megan M Langford; Shane A Perrine
Journal:  Hear Res       Date:  2013-05-25       Impact factor: 3.208

4.  Binge toluene exposure alters glutamate, glutamine and GABA in the adolescent rat brain as measured by proton magnetic resonance spectroscopy.

Authors:  Shane A Perrine; Shonagh K O'Leary-Moore; Matthew P Galloway; John H Hannigan; Scott E Bowen
Journal:  Drug Alcohol Depend       Date:  2010-12-03       Impact factor: 4.492

5.  Single prolonged stress decreases glutamate, glutamine, and creatine concentrations in the rat medial prefrontal cortex.

Authors:  Dayan Knox; Shane A Perrine; Sophie A George; Matthew P Galloway; Israel Liberzon
Journal:  Neurosci Lett       Date:  2010-05-28       Impact factor: 3.046

6.  Changes in the mitochondrial function and in the efficiency of energy transfer pathways during cardiomyocyte aging.

Authors:  Kersti Tepp; Marju Puurand; Natalja Timohhina; Jasper Adamson; Aleksandr Klepinin; Laura Truu; Igor Shevchuk; Vladimir Chekulayev; Tuuli Kaambre
Journal:  Mol Cell Biochem       Date:  2017-03-14       Impact factor: 3.396

7.  MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain.

Authors:  Shane A Perrine; Farhad Ghoddoussi; Mark S Michaels; Elisabeth M Hyde; Donald M Kuhn; Matthew P Galloway
Journal:  Neurotoxicology       Date:  2010-08-26       Impact factor: 4.294

8.  Region-specific alteration in brain glutamate: possible relationship to risk-taking behavior.

Authors:  Bernadette M Cortese; Todd R Mitchell; Matthew P Galloway; Kristen E Prevost; Jidong Fang; Gregory J Moore; Thomas W Uhde
Journal:  Physiol Behav       Date:  2009-12-13

9.  In vivo toxicometabolomics reveals multi-organ and urine metabolic changes in mice upon acute exposure to human-relevant doses of 3,4-methylenedioxypyrovalerone (MDPV).

Authors:  Ana Margarida Araújo; Márcia Carvalho; Vera Marisa Costa; José Alberto Duarte; Ricardo Jorge Dinis-Oliveira; Maria de Lourdes Bastos; Paula Guedes de Pinho; Félix Carvalho
Journal:  Arch Toxicol       Date:  2020-11-19       Impact factor: 5.153

10.  Large-scale neurochemical metabolomics analysis identifies multiple compounds associated with methamphetamine exposure.

Authors:  Joseph L McClay; Daniel E Adkins; Sarah A Vunck; Angela M Batman; Robert E Vann; Shaunna L Clark; Patrick M Beardsley; Edwin J C G van den Oord
Journal:  Metabolomics       Date:  2012-08-26       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.